International Journal of Molecular Medical Science, 2025, Vol.15, No.4, 175-184 http://medscipublisher.com/index.php/ijmms 183 Giau V., and An S., 2016, Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease, Journal of the Neurological Sciences, 360: 141-152. https://doi.org/10.1016/j.jns.2015.12.005 Grunt M., Failla A., Stevic I., Hillebrand T., and Schwarzenbach H., 2020, A novel assay for exosomal and cell-free miRNA isolation and quantification, RNA Biology, 17: 425-440. https://doi.org/10.1080/15476286.2020.1721204 Hill A., Cheng L., Doecke J., Sharples R., Villemagne V., Fowler C., Rembach A., Macaulay L., and Masters C., 2014, Exosomal mirna as biomarkers for diagnosing Alzheimer's disease, Alzheimer's and Dementia, 10: P299-P300. https://doi.org/10.1016/j.jalz.2014.04.501 Insel P., Weiner M., Mackin R., Mormino E., Lim Y., Stomrud E., Palmqvist S., Masters C., Maruff P., Hansson O., and Mattsson N., 2019, Determining clinically meaningful decline in preclinical Alzheimer disease, Neurology, 93: e322-e333. https://doi.org/10.1212/WNL.0000000000007831 Jain G., Stuendl A., Rao P., Berulava T., Centeno T., Kaurani L., Burkhardt S., Delalle I., Kornhuber J., Hüll M., Maier W., Peters O., Esselmann H., Schulte C., Deuschle C., Synofzik M., Wiltfang J., Mollenhauer B., Maetzler W., Schneider A., and Fischer A., 2019, A combined miRNA–piRNA signature to detect Alzheimer’s disease, Translational Psychiatry, 9(1): 250. https://doi.org/10.1038/s41398-019-0579-2 Jessen F., Spottke A., Boecker H., Brosseron F., Buerger K., Catak C., Fliessbach K., Franke C., Fuentes M., Heneka M., Janowitz D., Kilimann I., Laske C., Menne F., Nestor P., Peters O., Priller J., Pross V., Ramírez A., Schneider A., Speck O., Spruth E., Teipel S., Vukovich R., Westerteicher C., Wiltfang J., Wolfsgruber S., Wagner M., and Düzel E., 2018, Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE), Alzheimer's Research and Therapy, 10(2): 15. https://doi.org/10.1186/s13195-017-0314-2 Jutten R., Sikkes S., Van Der Flier W., Scheltens P., Visser P., and Tijms B., 2021, Finding treatment effects in alzheimer trials in the face of disease progression heterogeneity, Neurology, 96: e2673-e2684. https://doi.org/10.1212/WNL.0000000000012022 Kaur S., Verma H., Kaur S., Gangwar P., Yadav A., Yadav B., Rao R., Dhiman M., and Mantha A., 2023, Understanding the multifaceted role of miRNAs in Alzheimer's disease pathology, Metabolic Brain Disease, 39(1): 217-237. https://doi.org/10.1007/s11011-023-01265-9 Leidinger P., Backes C., Deutscher S., Schmitt K., Mueller S., Frese K., Haas J., Ruprecht K., Paul F., Stähler C., Lang C., Meder B., Bártfai T., Meese E., and Keller A., 2013, A blood based 12-miRNA signature of Alzheimer disease patients, Genome Biology, 14: R78. https://doi.org/10.1186/gb-2013-14-7-r78 Licursi V., Conte F., Fiscon G., and Paci P., 2019, Mienturnet: an interactive web tool for microRNA-target enrichment and network-based analysis, BMC Bioinformatics, 20(1): 545. https://doi.org/10.1186/s12859-019-3105-x Lu T., Lee C., Tsai M., Chiu Y., Hsiao C., Lai L., and Chuang E., 2012, MiRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets, PLoS One, 7(8): e42390. https://doi.org/10.1371/journal.pone.0042390 Lugli G., Cohen A., Bennett D., Shah R., Fields C., Hernandez A., and Smalheiser N., 2015, Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers, PLoS One, 10(10): e0139233. https://doi.org/10.1371/journal.pone.0139233 Malla B., Aebersold D., and Pra D., 2018, Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy, Journal of Translational Medicine, 16(1): 223. https://doi.org/10.1186/s12967-018-1592-6 Manna I., De Benedittis S., Quattrone A., Maisano D., Iaccino E., and Quattrone A., 2020, Exosomal miRNAs as potential diagnostic biomarkers in Alzheimer's disease, Pharmaceuticals, 13(9): 243. https://doi.org/10.3390/ph13090243 Mukherjee S., Mez J., Trittschuh E., Saykin A., Gibbons L., Fardo D., Wessels M., Bauman J., Moore M., Choi S., Gross A., Rich J., Louden D., Sanders R., Grabowski T., Bird T., McCurry S., Snitz B., Kamboh M., Lopez O., De Jager P., Bennett D., Keene C., Larson E., and Crane P., 2018, Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups, Molecular Psychiatry, 25: 2942-2951. https://doi.org/10.1038/s41380-018-0298-8 Nagaraj S., Zoltowska K., Laskowska-Kaszub K., and Wojda U., 2019, microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer, Ageing Research Reviews, 49: 125-143. https://doi.org/10.1016/j.arr.2018.10.008 Occhipinti G., Giulietti M., Principato G., and Piva F., 2016, The choice of endogenous controls in exosomal microRNA assessments from biofluids, Tumor Biology, 37: 11657-11665. https://doi.org/10.1007/s13277-016-5164-1 Pereira J., Teixeira L., Mamede I., Alves M., Caramelli P., Luizon M., Veloso A., and Gomes K., 2024, miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach, Journal of Neurochemistry, 168: 977-994.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==